# A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

> **NCT06688435** · PHASE1 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** SYS6020 injection

## Key facts

- **NCT ID:** NCT06688435
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2028-12-01
- **Final completion:** 2033-05-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06688435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06688435, "A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06688435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*